FormWeb • mosunetuzumab

UNC Health

UNC Health Medication Formulary

Change Request Form Chemical/SDS Search UNC Health.org

Add Formweb to your mobile device

Android iOS

Click here to submit safety event reports via SAFE

UNC Health

UNC Health Medication Formulary

Change Request Form Chemical/SDS Search UNC Health.org

Search results for:

mosunetuzumab

mosunetuzumab

Drug Name	Form	Strength
Mosunetuzumab-axgb	INJECTION, SUBCUTANEOUS	10 mg/mL (0.5 mL)
Mosunetuzumab-axgb	INJECTION, SUBCUTANEOUS	45 mg/mL (1mL)
Mosunetuzumab-axgb	SOLUTION, INTRAVENOUS	1 mg/mL (1 mL)
Mosunetuzumab-axgb	SOLUTION, INTRAVENOUS	1 mg/mL (30 mL)

UNC Health

System Formulary Restriction:

Mosunetuzumab-axgb orders must be signed by a Hematology/Oncology Attending Physician

Inpatient use of mosunetuzumab-axgb injection is restricted to patients who meet one of the following criteria:

Initiation/new-start treatment for relapsed/refractory follicular lymphoma
Re-initiation of treatment in patients with relapsed/refractory follicular lymphoma who have experienced a treatment delay that requires re-initiation with step-up doses

All other use is restricted to outpatient encounters or clinic use only (ie, no inpatient use)

Med Center
UNC Medical Center Formulary Restrictions

Last updated: Sep. 26, 2023

Black Box Warning: Cytokine Release Syndrome

This site is intended for the staff of UNC Health.
While others may view accessible pages, UNC Health makes no warranty, express or implied,
as to the use of this information outside of UNC Health.